StemCells, Inc. CEO Martin McGlynn Featured on BioBusiness.TV's "Stem Cell Review" Series
PALO ALTO , Calif. , November 23, 2009 – StemCells, Inc. (NASDAQ: STEM) announced today that its president and CEO, Martin McGlynn, was recently featured on BioBusiness.TV’s “Stem Cell Review” discussing the Company’s therapeutic product development programs, including the promise of human neural stem cells and the broad potential application of the Company’s lead product candidate, HuCNS-SC ® cells, in a variety of central nervous system (CNS) disorders. The Stem Cell Review is a 10-part series produced by BioBusiness.TV that covers the science, medical applications, and business of stem cells, and features leading authorities in the field.
Mr. McGlynn’s interview is part of the Stem Cell Review’s Episode 7: Neuronal Stem Cells and CNS disorders. The segment can be viewed online at http://biobusiness.tv/videos/219 and may also be accessed through the Company’s website at www.stemcellsinc.com.
About HuCNS-SC Cells
StemCells’ lead product candidate, HuCNS-SC cells, is a highly purified composition of human neural stem cells that are expanded and stored as banks of cells. The Company’s preclinical research has shown that HuCNS-SC cells can be directly transplanted in the central nervous system. The transplanted cells are able to engraft, migrate, differentiate into neurons and glial cells, and possess the ability to survive for as long as one year with no sign of tumor formation or adverse effects. These findings show that HuCNS-SC cells, when transplanted, behave like normal stem cells, suggesting the possibility of a continual replenishment of normal human neural cells.
StemCells has completed a Phase I clinical trial of its HuCNS-SC cells for the treatment of a Neuronal Ceroid Lipofuscinosis (NCL), a fatal brain disorder in children. Data from this trial demonstrated the clinical safety and tolerability of these cells. StemCells has also initiated at the University of California, San Francisco (UCSF) Children’s Hospital a Phase I trial of the HuCNS-SC cells in Pelizaeus-Merzbacher Disease (PMD), a fatal myelination disorder that primarily afflicts children. The human safety data that StemCells is accumulating for its HuCNS-SC cells through these clinical trials is expected to facilitate the pathway for future clinical testing in other central nervous system disorders, including retinal degenerative diseases, such as age-related macular degeneration and retinitis pigmentosa, and spinal cord injury.
About StemCells, Inc.
StemCells, Inc. is focused on the development and commercialization of cell-based technologies. In its cellular medicine programs, StemCells is targeting diseases of the central nervous system and liver. StemCells’ lead product candidate, HuCNS-SC cells (purified human neural stem cells), is in clinical development for the treatment of two fatal neurodegenerative disorders that primarily affect young children. StemCells also markets specialty cell culture media products under the brand SC Proven ®, and is developing its cell-based technologies for use in drug screening and drug development. Further information about StemCells is available at www.stemcellsinc.com.
Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the potential for the Company’s therapies to treat PMD, NCL and other serious neurodegenerative diseases, the potential for its cell-based therapeutics to treat other diseases or disorders, and the future business operations of the Company, including its ability to conduct clinical trials as well as its other research and product development efforts. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management’s current views and are based on certain assumptions that may or may not ultimately prove valid. The Company’s actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including the fact that additional trials will be required to demonstrate the safety and efficacy of the Company’s HuCNS-SC cells for the treatment of any disease; uncertainties regarding the ability of preclinical research, including research in animal models, to accurately predict success or failure in clinical trials; uncertainties regarding the Company’s ability to obtain the increased capital resources and regulatory approvals needed to continue its current and planned research and development operations; uncertainty as to whether HuCNS-SC and any products that may be generated in the future in the Company’s cell-based programs will prove safe and clinically effective and not cause tumors or other adverse side effects; uncertainties regarding the Company’s ability to commercialize a therapeutic product and its ability to successfully compete with other products on the market; and other factors that are described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2008, and in its subsequent reports on Form 10-Q and Form 8-K.
#########################
CONTACT: StemCells, Inc.
Megan Meloni
Investor Relations
650-475-3100, Ext. 105
irpr@stemcellsinc.com
Media
Tim Brons
Vida Communication, Inc.
415-675-7402
SOURCE: StemCells, Inc.
|
